Polymorphisms in Inflammatory Genes Modulate Clinical Complications in Patients With Sickle Cell Disease

Sickle cell disease (SCD), the most common monogenic disease worldwide, is marked by a phenotypic variability that is, to date, only partially understood. Because inflammation plays a major role in SCD pathophysiology, we hypothesized that single nucleotide polymorphisms (SNP) in genes encoding func...

Full description

Bibliographic Details
Main Authors: Karina Tozatto-Maio, Robert Girot, Indou Deme Ly, Ana Cristina Silva Pinto, Vanderson Rocha, Francisco Fernandes, Ibrahima Diagne, Yahia Benzerara, Carla L. Dinardo, Julia Pavan Soler, Simone Kashima, Itauá Leston Araujo, Chantal Kenzey, Guilherme H. H. Fonseca, Evandra S. Rodrigues, Fernanda Volt, Luciana Jarduli, Annalisa Ruggeri, Christina Mariaselvam, Sandra F. M. Gualandro, Hanadi Rafii, Barbara Cappelli, Felipe Melo Nogueira, Graziana Maria Scigliuolo, Renato Luiz Guerino-Cunha, Kelen Cristina Ribeiro Malmegrim, Belinda P. Simões, Eliane Gluckman, Ryad Tamouza
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.02041/full
id doaj-67cb8a7ed9504d0aaebc582eaf5a2b7d
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Karina Tozatto-Maio
Karina Tozatto-Maio
Karina Tozatto-Maio
Karina Tozatto-Maio
Robert Girot
Indou Deme Ly
Ana Cristina Silva Pinto
Ana Cristina Silva Pinto
Vanderson Rocha
Francisco Fernandes
Ibrahima Diagne
Yahia Benzerara
Carla L. Dinardo
Julia Pavan Soler
Simone Kashima
Simone Kashima
Itauá Leston Araujo
Chantal Kenzey
Chantal Kenzey
Guilherme H. H. Fonseca
Evandra S. Rodrigues
Evandra S. Rodrigues
Fernanda Volt
Fernanda Volt
Luciana Jarduli
Luciana Jarduli
Annalisa Ruggeri
Annalisa Ruggeri
Annalisa Ruggeri
Christina Mariaselvam
Sandra F. M. Gualandro
Hanadi Rafii
Hanadi Rafii
Barbara Cappelli
Barbara Cappelli
Felipe Melo Nogueira
Graziana Maria Scigliuolo
Graziana Maria Scigliuolo
Renato Luiz Guerino-Cunha
Renato Luiz Guerino-Cunha
Kelen Cristina Ribeiro Malmegrim
Belinda P. Simões
Eliane Gluckman
Eliane Gluckman
Ryad Tamouza
spellingShingle Karina Tozatto-Maio
Karina Tozatto-Maio
Karina Tozatto-Maio
Karina Tozatto-Maio
Robert Girot
Indou Deme Ly
Ana Cristina Silva Pinto
Ana Cristina Silva Pinto
Vanderson Rocha
Francisco Fernandes
Ibrahima Diagne
Yahia Benzerara
Carla L. Dinardo
Julia Pavan Soler
Simone Kashima
Simone Kashima
Itauá Leston Araujo
Chantal Kenzey
Chantal Kenzey
Guilherme H. H. Fonseca
Evandra S. Rodrigues
Evandra S. Rodrigues
Fernanda Volt
Fernanda Volt
Luciana Jarduli
Luciana Jarduli
Annalisa Ruggeri
Annalisa Ruggeri
Annalisa Ruggeri
Christina Mariaselvam
Sandra F. M. Gualandro
Hanadi Rafii
Hanadi Rafii
Barbara Cappelli
Barbara Cappelli
Felipe Melo Nogueira
Graziana Maria Scigliuolo
Graziana Maria Scigliuolo
Renato Luiz Guerino-Cunha
Renato Luiz Guerino-Cunha
Kelen Cristina Ribeiro Malmegrim
Belinda P. Simões
Eliane Gluckman
Eliane Gluckman
Ryad Tamouza
Polymorphisms in Inflammatory Genes Modulate Clinical Complications in Patients With Sickle Cell Disease
Frontiers in Immunology
sickle cell retinopathy
sickle cell disease
inflammation markers
NK cell receptors and ligands
toll-like receptor (TLR)
non-classical HLA
author_facet Karina Tozatto-Maio
Karina Tozatto-Maio
Karina Tozatto-Maio
Karina Tozatto-Maio
Robert Girot
Indou Deme Ly
Ana Cristina Silva Pinto
Ana Cristina Silva Pinto
Vanderson Rocha
Francisco Fernandes
Ibrahima Diagne
Yahia Benzerara
Carla L. Dinardo
Julia Pavan Soler
Simone Kashima
Simone Kashima
Itauá Leston Araujo
Chantal Kenzey
Chantal Kenzey
Guilherme H. H. Fonseca
Evandra S. Rodrigues
Evandra S. Rodrigues
Fernanda Volt
Fernanda Volt
Luciana Jarduli
Luciana Jarduli
Annalisa Ruggeri
Annalisa Ruggeri
Annalisa Ruggeri
Christina Mariaselvam
Sandra F. M. Gualandro
Hanadi Rafii
Hanadi Rafii
Barbara Cappelli
Barbara Cappelli
Felipe Melo Nogueira
Graziana Maria Scigliuolo
Graziana Maria Scigliuolo
Renato Luiz Guerino-Cunha
Renato Luiz Guerino-Cunha
Kelen Cristina Ribeiro Malmegrim
Belinda P. Simões
Eliane Gluckman
Eliane Gluckman
Ryad Tamouza
author_sort Karina Tozatto-Maio
title Polymorphisms in Inflammatory Genes Modulate Clinical Complications in Patients With Sickle Cell Disease
title_short Polymorphisms in Inflammatory Genes Modulate Clinical Complications in Patients With Sickle Cell Disease
title_full Polymorphisms in Inflammatory Genes Modulate Clinical Complications in Patients With Sickle Cell Disease
title_fullStr Polymorphisms in Inflammatory Genes Modulate Clinical Complications in Patients With Sickle Cell Disease
title_full_unstemmed Polymorphisms in Inflammatory Genes Modulate Clinical Complications in Patients With Sickle Cell Disease
title_sort polymorphisms in inflammatory genes modulate clinical complications in patients with sickle cell disease
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2020-09-01
description Sickle cell disease (SCD), the most common monogenic disease worldwide, is marked by a phenotypic variability that is, to date, only partially understood. Because inflammation plays a major role in SCD pathophysiology, we hypothesized that single nucleotide polymorphisms (SNP) in genes encoding functionally important inflammatory proteins might modulate the occurrence of SCD complications. We assessed the association between 20 SNPs in genes encoding Toll-like receptors (TLR), NK cell receptors (NKG), histocompatibility leukocyte antigens (HLA), major histocompatibility complex class I polypeptide-related sequence A (MICA) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and the occurrence of six SCD clinical complications (stroke, acute chest syndrome (ACS), leg ulcers, cholelithiasis, osteonecrosis, or retinopathy). This study was performed in a cohort of 500 patients. We found that the TLR2 rs4696480 TA, TLR2 rs3804099 CC, and HLA-G, rs9380142 AA genotypes were more frequent in patients who had fewer complications. Also, in logistic regression, the HLA-G rs9380142 G allele increased the risk of cholelithiasis (AG vs. AA, OR 1.57, 95%CI 1.16–2.15; GG vs. AA, OR 2.47, 95%CI 1.34–4.64; P = 0.02). For SNPs located in the NKG2D loci, in logistic regression, the A allele in three SNPs was associated with a lower frequency of retinopathy, namely, rs2246809 (AA vs. GG: OR 0.22, 95%CI 0.09–0.50; AG vs. GG: OR 0.47, 95%CI 0.31–0.71; P = 0.004, for patients of same origin), rs2617160 (AT vs. TT: OR 0.67, 95%CI 0.48–0.92; AA vs. TT: OR 0.45, 95%CI 0.23–0.84; P = 0.04), and rs2617169 (AA vs. TT: OR 0.33, 95%CI 0.13–0.82; AT vs. TT: OR 0.58, 95%CI 0.36–0.91, P = 0.049, in patients of same SCD genotype). These results, by uncovering susceptibility to, or protection against SCD complications, might contribute to a better understanding of the inflammatory pathways involved in SCD manifestations and to pave the way for the discovery of biomarkers that predict disease severity, which would improve SCD management.
topic sickle cell retinopathy
sickle cell disease
inflammation markers
NK cell receptors and ligands
toll-like receptor (TLR)
non-classical HLA
url https://www.frontiersin.org/article/10.3389/fimmu.2020.02041/full
work_keys_str_mv AT karinatozattomaio polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT karinatozattomaio polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT karinatozattomaio polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT karinatozattomaio polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT robertgirot polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT indoudemely polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT anacristinasilvapinto polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT anacristinasilvapinto polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT vandersonrocha polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT franciscofernandes polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT ibrahimadiagne polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT yahiabenzerara polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT carlaldinardo polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT juliapavansoler polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT simonekashima polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT simonekashima polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT itaualestonaraujo polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT chantalkenzey polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT chantalkenzey polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT guilhermehhfonseca polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT evandrasrodrigues polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT evandrasrodrigues polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT fernandavolt polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT fernandavolt polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT lucianajarduli polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT lucianajarduli polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT annalisaruggeri polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT annalisaruggeri polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT annalisaruggeri polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT christinamariaselvam polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT sandrafmgualandro polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT hanadirafii polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT hanadirafii polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT barbaracappelli polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT barbaracappelli polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT felipemelonogueira polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT grazianamariascigliuolo polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT grazianamariascigliuolo polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT renatoluizguerinocunha polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT renatoluizguerinocunha polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT kelencristinaribeiromalmegrim polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT belindapsimoes polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT elianegluckman polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT elianegluckman polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
AT ryadtamouza polymorphismsininflammatorygenesmodulateclinicalcomplicationsinpatientswithsicklecelldisease
_version_ 1724582662189875200
spelling doaj-67cb8a7ed9504d0aaebc582eaf5a2b7d2020-11-25T03:28:48ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-09-011110.3389/fimmu.2020.02041553988Polymorphisms in Inflammatory Genes Modulate Clinical Complications in Patients With Sickle Cell DiseaseKarina Tozatto-Maio0Karina Tozatto-Maio1Karina Tozatto-Maio2Karina Tozatto-Maio3Robert Girot4Indou Deme Ly5Ana Cristina Silva Pinto6Ana Cristina Silva Pinto7Vanderson Rocha8Francisco Fernandes9Ibrahima Diagne10Yahia Benzerara11Carla L. Dinardo12Julia Pavan Soler13Simone Kashima14Simone Kashima15Itauá Leston Araujo16Chantal Kenzey17Chantal Kenzey18Guilherme H. H. Fonseca19Evandra S. Rodrigues20Evandra S. Rodrigues21Fernanda Volt22Fernanda Volt23Luciana Jarduli24Luciana Jarduli25Annalisa Ruggeri26Annalisa Ruggeri27Annalisa Ruggeri28Christina Mariaselvam29Sandra F. M. Gualandro30Hanadi Rafii31Hanadi Rafii32Barbara Cappelli33Barbara Cappelli34Felipe Melo Nogueira35Graziana Maria Scigliuolo36Graziana Maria Scigliuolo37Renato Luiz Guerino-Cunha38Renato Luiz Guerino-Cunha39Kelen Cristina Ribeiro Malmegrim40Belinda P. Simões41Eliane Gluckman42Eliane Gluckman43Ryad Tamouza44Eurocord, Université de Paris, IRSL, Hopital Saint Louis, Paris, FranceMonacord, International Observatory on Sickle Cell Disease, Centre Scientifique de Monaco, Monaco, MonacoFaculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, BrazilDisciplina de Hematologia e Hemoterapia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, BrazilCHU Tenon, Paris, FranceNational Children Hospital Center Albert Royer, Cheikh Anta Diop University, Dakar, SenegalFaculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, BrazilCenter for Cell-based Therapy, Regional Blood Center of Ribeirão Preto, University of São Paulo, Ribeirão Preto, BrazilDisciplina de Hematologia e Hemoterapia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, BrazilInstituto de Matematica e Estatistica da Universidade de São Paulo, São Paulo, BrazilNational Children Hospital Center Albert Royer, Cheikh Anta Diop University, Dakar, SenegalDépartement de Bactériologie, Hôpital Saint-Antoine, Hôpitaux de l'Est parisien, Paris, FranceDisciplina de Hematologia e Hemoterapia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, BrazilInstituto de Matematica e Estatistica da Universidade de São Paulo, São Paulo, BrazilFaculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, BrazilCenter for Cell-based Therapy, Regional Blood Center of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil0INSERM 1160, Université Paris 7, Paris, FranceEurocord, Université de Paris, IRSL, Hopital Saint Louis, Paris, FranceMonacord, International Observatory on Sickle Cell Disease, Centre Scientifique de Monaco, Monaco, MonacoDisciplina de Hematologia e Hemoterapia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, BrazilFaculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, BrazilCenter for Cell-based Therapy, Regional Blood Center of Ribeirão Preto, University of São Paulo, Ribeirão Preto, BrazilEurocord, Université de Paris, IRSL, Hopital Saint Louis, Paris, FranceMonacord, International Observatory on Sickle Cell Disease, Centre Scientifique de Monaco, Monaco, MonacoCenter for Cell-based Therapy, Regional Blood Center of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil1School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, BrazilEurocord, Université de Paris, IRSL, Hopital Saint Louis, Paris, France2Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy3Cellular Therapy and Immunobiology Working Party, The European Society for Blood and Marrow Transplantation, Paris, France4INSERM U955, CHU Henri Mondor, Créteil, FranceDisciplina de Hematologia e Hemoterapia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, BrazilEurocord, Université de Paris, IRSL, Hopital Saint Louis, Paris, FranceMonacord, International Observatory on Sickle Cell Disease, Centre Scientifique de Monaco, Monaco, MonacoEurocord, Université de Paris, IRSL, Hopital Saint Louis, Paris, FranceMonacord, International Observatory on Sickle Cell Disease, Centre Scientifique de Monaco, Monaco, MonacoDisciplina de Hematologia e Hemoterapia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, BrazilEurocord, Université de Paris, IRSL, Hopital Saint Louis, Paris, FranceMonacord, International Observatory on Sickle Cell Disease, Centre Scientifique de Monaco, Monaco, MonacoFaculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, BrazilCenter for Cell-based Therapy, Regional Blood Center of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil1School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, BrazilFaculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, BrazilEurocord, Université de Paris, IRSL, Hopital Saint Louis, Paris, FranceMonacord, International Observatory on Sickle Cell Disease, Centre Scientifique de Monaco, Monaco, Monaco4INSERM U955, CHU Henri Mondor, Créteil, FranceSickle cell disease (SCD), the most common monogenic disease worldwide, is marked by a phenotypic variability that is, to date, only partially understood. Because inflammation plays a major role in SCD pathophysiology, we hypothesized that single nucleotide polymorphisms (SNP) in genes encoding functionally important inflammatory proteins might modulate the occurrence of SCD complications. We assessed the association between 20 SNPs in genes encoding Toll-like receptors (TLR), NK cell receptors (NKG), histocompatibility leukocyte antigens (HLA), major histocompatibility complex class I polypeptide-related sequence A (MICA) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and the occurrence of six SCD clinical complications (stroke, acute chest syndrome (ACS), leg ulcers, cholelithiasis, osteonecrosis, or retinopathy). This study was performed in a cohort of 500 patients. We found that the TLR2 rs4696480 TA, TLR2 rs3804099 CC, and HLA-G, rs9380142 AA genotypes were more frequent in patients who had fewer complications. Also, in logistic regression, the HLA-G rs9380142 G allele increased the risk of cholelithiasis (AG vs. AA, OR 1.57, 95%CI 1.16–2.15; GG vs. AA, OR 2.47, 95%CI 1.34–4.64; P = 0.02). For SNPs located in the NKG2D loci, in logistic regression, the A allele in three SNPs was associated with a lower frequency of retinopathy, namely, rs2246809 (AA vs. GG: OR 0.22, 95%CI 0.09–0.50; AG vs. GG: OR 0.47, 95%CI 0.31–0.71; P = 0.004, for patients of same origin), rs2617160 (AT vs. TT: OR 0.67, 95%CI 0.48–0.92; AA vs. TT: OR 0.45, 95%CI 0.23–0.84; P = 0.04), and rs2617169 (AA vs. TT: OR 0.33, 95%CI 0.13–0.82; AT vs. TT: OR 0.58, 95%CI 0.36–0.91, P = 0.049, in patients of same SCD genotype). These results, by uncovering susceptibility to, or protection against SCD complications, might contribute to a better understanding of the inflammatory pathways involved in SCD manifestations and to pave the way for the discovery of biomarkers that predict disease severity, which would improve SCD management.https://www.frontiersin.org/article/10.3389/fimmu.2020.02041/fullsickle cell retinopathysickle cell diseaseinflammation markersNK cell receptors and ligandstoll-like receptor (TLR)non-classical HLA